What is the recommended management for a patient with unknown or Rh‑negative RhD status, including type‑and‑screen testing and Rh immune globulin prophylaxis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of RhD-Negative or Unknown RhD Status

All pregnant patients should undergo RhD blood typing at the first prenatal visit, and RhD-negative unsensitized patients should receive Rh immune globulin (RhIG) at 28 weeks' gestation and again within 72 hours postpartum if the newborn is RhD-positive. 1

Initial Testing and Screening

Blood Type Determination

  • Perform RhD typing on all pregnant patients at the first prenatal visit
  • Include antibody screening to detect pre-existing alloimmunization
  • If RhD status is unknown or uncertain, treat the patient as RhD-negative until proven otherwise 1

Special Consideration: Weak D Phenotype

When laboratory reports indicate a "serologic weak D phenotype":

  • Request RHD genotyping to distinguish between weak D types and partial D phenotypes 2, 3
  • Weak D types 1,2, or 3: Manage as RhD-positive (no RhIG needed)
  • Partial D phenotypes: Manage as RhD-negative (RhIG required)
  • If genotyping is unavailable or results are pending, default to treating as RhD-negative 1

RhIG Prophylaxis Protocol

Routine Antepartum Administration

At 28 weeks' gestation:

  • Administer 300 mcg RhIG to all unsensitized RhD-negative patients
  • This reduces alloimmunization risk from 1.8% to 0.1-0.2% 1, 4

Postpartum Administration

Within 72 hours of delivery:

  • Confirm newborn's RhD status
  • If newborn is RhD-positive or unknown: Administer 300 mcg RhIG
  • Screen for excess fetomaternal hemorrhage (>15 mL fetal RBCs) using Kleihauer-Betke or flow cytometry
  • Do NOT use rosette test if newborn has weak D phenotype (high false-negative rate) 2
  • If >15 mL fetal blood detected: Calculate additional RhIG dose (10 mcg per mL fetal blood)

Sensitizing Events Requiring RhIG

Second and Third Trimester (≥12 weeks):

  • Spontaneous or induced abortion
  • Ectopic pregnancy
  • Amniocentesis or chorionic villus sampling
  • Cordocentesis
  • External cephalic version
  • Abdominal trauma
  • Antepartum hemorrhage
  • Intrauterine fetal death
  • Dose: 300 mcg within 72 hours of event 1, 5

First Trimester (<12 weeks): This remains controversial with conflicting guidelines:

  • Society for Maternal-Fetal Medicine (2024) recommends: Offer both RhD testing and RhIG administration for spontaneous and induced abortion <12 weeks when logistically feasible 6

    • Rationale: Fetal RBCs express D-antigen as early as 6 weeks; existing data insufficient to prove safety of withholding
    • Risk of alloimmunization is low but not zero
    • Prevention of future HDFN outweighs minimal risks of RhIG
  • Alternative approach (WHO, SFP): Forgo RhIG <12 weeks based on cost-effectiveness and very low risk

    • French guidelines (2025) also recommend against routine first-trimester RhIG 7

Clinical recommendation: In settings where RhIG is accessible and does not impede care access, administer RhIG for first-trimester events given the severe consequences of HDFN and inadequate evidence proving safety of omission 6

Emerging Technology: Cell-Free Fetal DNA Testing

Consider cfDNA testing for fetal RhD genotype in select cases:

  • Can identify RhD-negative fetuses in RhD-negative mothers (30-40% of cases)
  • Allows avoidance of unnecessary RhIG administration
  • Current limitations: Insufficient US population data, lack of standardization 8
  • Most useful during RhIG shortage situations or in alloimmunized patients for monitoring decisions 8

Critical Pitfalls to Avoid

  1. Never assume RhD-positive status without confirmation - if uncertain, give RhIG 1

  2. Do not use rosette test for fetomaternal hemorrhage screening if newborn has weak D phenotype - use Kleihauer-Betke or flow cytometry instead 2

  3. Do not perform unnecessary antiglobulin testing on maternal samples with negative immediate-spin reactions - this can lead to incorrect withholding of RhIG 2

  4. Do not delay RhIG beyond 72 hours - efficacy decreases significantly after this window 1

  5. Recognize that live virus vaccines (MMR, varicella) should be delayed 3 months after RhIG administration due to antibody interference 1

  6. Document clearly: Use consistent terminology when reporting weak D phenotypes to avoid confusion 3

Special Populations

Trauma Patients Receiving O+ Blood Products

  • RhD-negative females of childbearing age exposed to low-titer O+ whole blood have ~20% alloimmunization risk 9
  • Calculate RBC volume transfused relative to total blood volume
  • If <20% total blood volume: Administer RhIG
  • If >20% total blood volume: RhIG insufficient; screen for anti-D antibodies at 6-12 months 10

Alloimmunized Pregnancies

Once alloimmunization has occurred, management shifts to fetal monitoring:

  • Use middle cerebral artery peak systolic velocity Doppler for anemia detection 9
  • Consider IVIG in high-risk cases (prior fetal loss or severe anemia <24 weeks) 9
  • Continue intrauterine transfusions until 35 weeks if needed 9
  • Deliver between 37+0 and 38+6 weeks 9

References

Research

A Guide to Terminology for Rh Immunoprophylaxis.

Obstetrics and gynecology, 2017

Research

Rhesus D Prophylaxis: When and Why We Give Rhesus D Immunoglobulin.

Obstetrical & gynecological survey, 2025

Research

Prevention of RhD alloimmunization in the first trimester of pregnancy: Clinical practice guidelines of the French College of Obstetricians and Gynecologists.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2025

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.